Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.

ABSTRACT: Glioblastoma (GBM) is one of the deadliest human cancers. Because of the extremely unfavorable prognosis of GBM, it is important to develop more effective diagnostic and therapeutic strategies based on biologically and clinically relevant subclassification systems. Analyzing a collection of seventeen patient-derived glioblastoma stem-like cells (GSCs) by gene expression profiling, NMR spectroscopy and signal transduction pathway activation, we identified two GSC clusters, one characterized by a pro-neural-like phenotype and the other showing a mesenchymal-like phenotype. Evaluating the levels of proteins differentially expressed by the two GSC clusters in the TCGA GBM sample collection, we found that SRC activation is associated with a GBM subgroup showing better prognosis whereas activati

SUBMITTER: Marziali G 

PROVIDER: S-EPMC4746700 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature